Sample ClaimUse baseline: amyloid therapy claim-state read.
NC-2026-001-AD
ClaimUse baseline format
Each baseline follows this structure. Private baselines include more detail and the full evidence trail. This public sample shows the format with an illustrative example.
Current coverage restrictions remain justified
The public record shows available evidence has not yet changed enough, so broader routine coverage outside tightly defined patient-selection, biomarker-confirmation, and safety-monitoring criteria. The evidence supports slowing of cognitive decline in this population with established safety monitoring requirements.
The claim is stabilized but caveated: the restriction may narrow to biomarker-confirmed subgroups as real-world safety data accumulates. Key caveats: Qualify the evidence statement to apply strictly to biomarker-confirmed early Alzheimer's disease matching the trial inclusion criteria, and mandate continuous monitoring for Amyloid-Related Imaging Abnormalities (ARIA).
Every finding traces to a specific revision, citation event, or editorial signal in the public record. Re-review triggers: Publication of updated multi-society clinical practice guidelines; FDA safety labeling revision regarding ARIA monitoring frequency.
This sample shows the format with illustrative language. Real baselines include specific drug timelines with named data events — what changed, when, backed by which citation. Request one to see what a live baseline looks like for your asset or claim.
Send your asset or claim for scoping.
No charge, no commitment. We confirm whether it fits the baseline framework.